BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 15838659)

  • 1. Single nucleotide polymorphisms modify the transporter activity of ABCG2.
    Morisaki K; Robey RW; Ozvegy-Laczka C; Honjo Y; Polgar O; Steadman K; Sarkadi B; Bates SE
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):161-72. PubMed ID: 15838659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
    Mizuarai S; Aozasa N; Kotani H
    Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N.
    Vethanayagam RR; Wang H; Gupta A; Zhang Y; Lewis F; Unadkat JD; Mao Q
    Drug Metab Dispos; 2005 Jun; 33(6):697-705. PubMed ID: 15743976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy.
    Kim IS; Kim HG; Kim DC; Eom HS; Kong SY; Shin HJ; Hwang SH; Lee EY; Lee GW
    Cancer Sci; 2008 Dec; 99(12):2496-501. PubMed ID: 19032367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.
    Tamura A; Watanabe M; Saito H; Nakagawa H; Kamachi T; Okura I; Ishikawa T
    Mol Pharmacol; 2006 Jul; 70(1):287-96. PubMed ID: 16608919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism.
    Pollex EK; Anger G; Hutson J; Koren G; Piquette-Miller M
    Drug Metab Dispos; 2010 May; 38(5):740-4. PubMed ID: 20159988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.
    Tamura A; Wakabayashi K; Onishi Y; Takeda M; Ikegami Y; Sawada S; Tsuji M; Matsuda Y; Ishikawa T
    Cancer Sci; 2007 Feb; 98(2):231-9. PubMed ID: 17297656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the gout-causing Q141K polymorphism and a CFTR ΔF508 mimicking mutation on the processing and stability of the ABCG2 protein.
    Sarankó H; Tordai H; Telbisz Á; Özvegy-Laczka C; Erdős G; Sarkadi B; Hegedűs T
    Biochem Biophys Res Commun; 2013 Jul; 437(1):140-5. PubMed ID: 23800412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2.
    Ripperger A; Benndorf RA
    Biochem Pharmacol; 2016 Mar; 104():139-47. PubMed ID: 26903388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.
    Furukawa T; Wakabayashi K; Tamura A; Nakagawa H; Morishima Y; Osawa Y; Ishikawa T
    Pharm Res; 2009 Feb; 26(2):469-79. PubMed ID: 18958403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1).
    Honjo Y; Morisaki K; Huff LM; Robey RW; Hung J; Dean M; Bates SE
    Cancer Biol Ther; 2002; 1(6):696-702. PubMed ID: 12642696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional analysis of SNPs variants of BCRP/ABCG2.
    Kondo C; Suzuki H; Itoda M; Ozawa S; Sawada J; Kobayashi D; Ieiri I; Mine K; Ohtsubo K; Sugiyama Y
    Pharm Res; 2004 Oct; 21(10):1895-903. PubMed ID: 15553238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine.
    Kim HS; Sunwoo YE; Ryu JY; Kang HJ; Jung HE; Song IS; Kim EY; Shim JC; Shon JH; Shin JG
    Br J Clin Pharmacol; 2007 Nov; 64(5):645-54. PubMed ID: 17509035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.
    Robey RW; Honjo Y; Morisaki K; Nadjem TA; Runge S; Risbood M; Poruchynsky MS; Bates SE
    Br J Cancer; 2003 Nov; 89(10):1971-8. PubMed ID: 14612912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Joint effects of alcohol consumption and ABCG2 Q141K on chronic tophaceous gout risk.
    Tu HP; Ko AM; Chiang SL; Lee SS; Lai HM; Chung CM; Huang CM; Lee CH; Kuo TM; Hsieh MJ; Ko YC
    J Rheumatol; 2014 Apr; 41(4):749-58. PubMed ID: 24532835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
    Imai Y; Nakane M; Kage K; Tsukahara S; Ishikawa E; Tsuruo T; Miki Y; Sugimoto Y
    Mol Cancer Ther; 2002 Jun; 1(8):611-6. PubMed ID: 12479221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs.
    Tamura A; Onishi Y; An R; Koshiba S; Wakabayashi K; Hoshijima K; Priebe W; Yoshida T; Kometani S; Matsubara T; Mikuriya K; Ishikawa T
    Drug Metab Pharmacokinet; 2007 Dec; 22(6):428-40. PubMed ID: 18159130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
    Miwa M; Tsukahara S; Ishikawa E; Asada S; Imai Y; Sugimoto Y
    Int J Cancer; 2003 Dec; 107(5):757-63. PubMed ID: 14566825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
    Ahmed-Belkacem A; Pozza A; Muñoz-Martínez F; Bates SE; Castanys S; Gamarro F; Di Pietro A; Pérez-Victoria JM
    Cancer Res; 2005 Jun; 65(11):4852-60. PubMed ID: 15930306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.
    Bates SE; Medina-Pérez WY; Kohlhagen G; Antony S; Nadjem T; Robey RW; Pommier Y
    J Pharmacol Exp Ther; 2004 Aug; 310(2):836-42. PubMed ID: 15075385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.